GB2018591B - Use of antiestrogens and antigonado-tropically active antiandrogens for treatmnet of prostate hyperplasia and pharmaceutical preparatios and packs suitable for such use - Google Patents

Use of antiestrogens and antigonado-tropically active antiandrogens for treatmnet of prostate hyperplasia and pharmaceutical preparatios and packs suitable for such use

Info

Publication number
GB2018591B
GB2018591B GB7912416A GB7912416A GB2018591B GB 2018591 B GB2018591 B GB 2018591B GB 7912416 A GB7912416 A GB 7912416A GB 7912416 A GB7912416 A GB 7912416A GB 2018591 B GB2018591 B GB 2018591B
Authority
GB
United Kingdom
Prior art keywords
preparatios
antigonado
treatmnet
tropically
antiestrogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB7912416A
Other languages
English (en)
Other versions
GB2018591A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of GB2018591A publication Critical patent/GB2018591A/en
Application granted granted Critical
Publication of GB2018591B publication Critical patent/GB2018591B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GB7912416A 1978-04-17 1979-04-09 Use of antiestrogens and antigonado-tropically active antiandrogens for treatmnet of prostate hyperplasia and pharmaceutical preparatios and packs suitable for such use Expired GB2018591B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782817157 DE2817157A1 (de) 1978-04-17 1978-04-17 Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie

Publications (2)

Publication Number Publication Date
GB2018591A GB2018591A (en) 1979-10-24
GB2018591B true GB2018591B (en) 1982-09-08

Family

ID=6037493

Family Applications (1)

Application Number Title Priority Date Filing Date
GB7912416A Expired GB2018591B (en) 1978-04-17 1979-04-09 Use of antiestrogens and antigonado-tropically active antiandrogens for treatmnet of prostate hyperplasia and pharmaceutical preparatios and packs suitable for such use

Country Status (13)

Country Link
US (1) US4310523A (enExample)
JP (1) JPS5513261A (enExample)
AU (1) AU528179B2 (enExample)
BE (1) BE875634A (enExample)
CA (1) CA1134271A (enExample)
CH (1) CH641679A5 (enExample)
DE (1) DE2817157A1 (enExample)
GB (1) GB2018591B (enExample)
IT (1) IT1119733B (enExample)
LU (1) LU81153A1 (enExample)
NL (1) NL7901961A (enExample)
SE (1) SE441977B (enExample)
ZA (1) ZA791797B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
US4885289A (en) * 1983-12-12 1989-12-05 Breuer Miklos M Alteration of character of male beard growth
DE3486090T2 (de) * 1983-12-12 1993-08-05 Kaszynski Edwin G Haarwuchsmodifikation.
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
ES2072424T3 (es) 1989-01-27 1995-07-16 Immunolytics Inc Formula y metodo para el tratamiento de hipertrofias prostaticas benignas.
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
CA2062973C (en) * 1989-07-07 2003-09-23 Fernand Labrie Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5411991A (en) * 1992-12-22 1995-05-02 Shander; Douglas Method of reducing hair growth employing sulfhydryl active compounds
US6743419B1 (en) 1992-12-22 2004-06-01 The Gillette Company Method of reducing hair growth employing sulfhydryl active compounds
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE232743T1 (de) * 1994-06-27 2003-03-15 Neutron Therapies Inc Bor enthaltende hormonanaloga und verfahren fuer ihre verwendung zur bildlichen darstellung oder zum abtoeten von zellen, die hormonrezeptoren besitzen
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU5984196A (en) * 1995-06-07 1996-12-30 Merck & Co., Inc. Treatment and prevention of prostatic disease
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
MXPA00008868A (es) * 1998-03-11 2003-04-25 Endorech Inc Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso.
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
HUP0303172A3 (en) * 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
AU2001271163A1 (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
RU2188000C1 (ru) * 2001-09-27 2002-08-27 Нестерук Владимир Викторович Лекарственное средство на основе тамоксифена
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
PT2101731T (pt) 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
US8288342B2 (en) * 2008-10-10 2012-10-16 Teva Women's Health, Inc. Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076823A (en) * 1961-07-03 1963-02-05 Syntex Corp Process for the production of 6-chloro-3-keto-deta steroid compounds
US3423507A (en) * 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US4055641A (en) * 1976-05-10 1977-10-25 Richardson-Merrell Inc. Method of treating benign prostatic hypertrophy

Also Published As

Publication number Publication date
DE2817157A1 (de) 1979-10-25
IT1119733B (it) 1986-03-10
JPS645007B2 (enExample) 1989-01-27
GB2018591A (en) 1979-10-24
SE7903240L (sv) 1979-10-18
SE441977B (sv) 1985-11-25
CH641679A5 (de) 1984-03-15
US4310523A (en) 1982-01-12
ZA791797B (en) 1980-11-26
BE875634A (fr) 1979-10-17
CA1134271A (en) 1982-10-26
JPS5513261A (en) 1980-01-30
IT7921854A0 (it) 1979-04-13
AU4560479A (en) 1979-10-25
AU528179B2 (en) 1983-04-21
LU81153A1 (de) 1979-06-19
NL7901961A (nl) 1979-10-19

Similar Documents

Publication Publication Date Title
GB2018591A (en) Use of antiestrogens and antigonado-tropically active antiandrogens for treatmnet of prostate hyperplasia and pharmaceutical preparatios and packs suitable for such use
JPS56139422A (en) Sterilized and therapeutically active protein composition
IL60890A0 (en) Preparations for the treatment of theileriosic containing piperidyl acetonyl-quinazolinone deravatives and some new such compounds
PT65244B (en) Pharmaceutically active complexes and pharmaceutical compositions containing them
ZA804514B (en) Pharmacologically active substituted 3-amino-sydnone-imines processes for their preparation and their use
NO834089L (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser av platina og palladium
CS193554B2 (en) Insecticide means and method of making the active substance
JPS5511570A (en) Antiipsoriasis active substance and its manufacture
NO830238L (no) Fremgangsmaate for fremstilling av farmakologisk aktive urinstoffer og tiourinstoffer
ZA775980B (en) Medicament pack and agent for the treatment of climacteric deficiency symptoms
GB2058562B (en) Pharmaceutical compositions containing paracetamol and ascorbic acid
IT1173708B (it) Dispositivo chirurgico contenente sostanza farmaceutica ed emissione protratta
DE2964696D1 (en) N-(benzothienopyrazol)-amides and pharmaceutical compositions containing them
NO151319C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive beta-mono-fluormetyl-beta-alanin- og beta-difluormetyl-beta-alanin-forbindelser
JPS54140713A (en) Surgical antiiinflammatory and anodyne agent
NO168644C (no) Fremgangsmaate for fremstilling av terapeutisk aktive n-(pyrrol-1-yl)pyridinaminer
CS189594B2 (en) Fungicide means and method of preparation of the active substance
JPS5246055A (en) Benzimidoyl thionothiolphosphate ester and insecticide and antiitick agent containing same
NO802277L (no) Fremgangsmaate til fremstilling av terapeutisk aktive 25-halocholest-5-en-3beta,22-dioler og estere derav
CS222299B2 (en) Method of treating the dragee from soft gelatine containing pharmaceutically active substance in its covering
PH16641A (en) Benzimidazoles and pharmaceutical preparations containing such compounds
CS193067B2 (en) Herbicide means and method of making the active agents
CS189033B2 (en) Herbicide means and method of making the active substance
GB2014786B (en) Arrangement for the connection and enclosure of at least one semiconductor member
GB2117238B (en) Morniflumate pharmaceutical compositions having antiinflammatory analgesic antipyretic and gastroprotective activity

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee